Sustained-release injectable composition comprising finasteride
US11484495B2 · kind B2 · utility
0Cited by
1References
7Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Dec 21, 2020 |
| Grant date | Nov 1, 2022 |
| Priority date | — |
| Expiry date | Dec 21, 2040 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P17/14
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present disclosure relates to a sustained-release injectable composition comprising finasteride, and when the composition is injected as an injection formulation, it is possible to maintain a constant blood concentration for a long time without initial over-release in terms of the degree of release of finasteride, and when the composition is administrated by subcutaneous injection, it is possible to maintain the effect of treating hair loss and benign prostatic hyperplasia continuously for 1 to 3 months.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.